Cidara Therapeutics (CDTX) said Monday that its phase 2b trial evaluating CD388, its long-acting antiviral for seasonal influenza prevention, met its primary and secondary endpoints.
The study showed that a single dose of CD388 provided 76.1% protection at 450 mg, 61.3% at 300 mg, and 57.7% at 150 mg against symptomatic influenza over 24 weeks.
CD388 was well tolerated with no adverse events observed, the company said.
Cidara said it has submitted an end-of-phase 2 meeting request to the US Food and Drug Administration to discuss plans for a phase 3 trial.
Cidara shares surged 83% in pre-market trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。